Phase I
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
One day after falsified information regarding its Phase I/II breast cancer data circulated online, Olema Pharmaceuticals released its topline data for a potential best-in-class complete estrogen receptor antagonist.
In October, Vertex Pharmaceuticals announced stunning results in a type 1 diabetes patient who had been dosed with the company’s experimental therapy.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
Positive data from an ongoing Phase Ib study has impressed investors in Aptevo Therapeutics.
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
If the road to success is paved with failures, then the road to an effective, approved drug is paved with flops. Merck and Enanta are adding some painful pavers to their own roads this week.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
PRESS RELEASES